All In Biotech

Drug Trial Radar · NCT06439836

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

Phase 1 Trial of CA-4948 in Combination With Pembrolizumab to Overcome Resistance to PD-1/PD-L1 Blockade in Metastatic Urothelial Cancer

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

27

Planned (sponsor's estimate)

Start

May 5, 2025

Primary completion

Jun 1, 2027

Study completion Jun 1, 2027

Sponsor

Sponsor type
NIH
First posted
Jun 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial tests the safety, side effects, best dose, and effectiveness of emavusertib (CA-4948) in combination with pembrolizumab in treating patients with urothelial cancer that has spread from where it first started to other places in the body (metastatic) and that has a resistance to PD-1/PD-L1 immune checkpoint inhibitors. CA-4948, a kinase inhibitor, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving CA-4948 in combination with pembrolizumab may be safe, tolerable and/or effective in treating patients with metastatic urothelial cancer that is resistant to PD-1/PD-L1 immune checkpoint inhibitors.

Conditions

  • Metastatic Urothelial Carcinoma
  • Unresectable Urothelial Carcinoma

Interventions

  • Biopsy ProcedureProcedure

    Undergo tumor biopsy

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Computed TomographyProcedure

    Undergo CT

  • EmavusertibBiological

    Given PO

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • PembrolizumabBiological

    Given IV

  • Positron Emission TomographyProcedure

    Undergo PET

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicities (DLTs)Time frame: Up to completion of cycle 1
  2. Recommended phase 2 dose (RP2D)Time frame: Up to completion of cycle 1
  3. Incidence of AEsTime frame: Up to 30 days after last dose of study treatment

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope Comprehensive Cancer Center

    Duarte, California · Recruiting

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California · Recruiting

  • UC San Diego Moores Cancer Center

    La Jolla, California · Recruiting

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California · Recruiting

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami, Florida · Recruiting

  • Emory University Hospital Midtown

    Atlanta, Georgia · Recruiting

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia · Recruiting

  • Emory Saint Joseph's Hospital

    Atlanta, Georgia · Recruiting

  • Mount Sinai Hospital

    New York, New York · Recruiting

  • NYP/Weill Cornell Medical Center

    New York, New York · Recruiting

  • UT Southwestern/Simmons Cancer Center-Dallas

    Dallas, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.